Daniel Z Press. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antiparkinson Agents/therapeutic useCholinesterase Inhibitors/adverse effectsCholinesterase Inhibitors/therapeutic useDementia/drug therapyDementia/etiologyDisease ProgressionHumansLewy Body Disease/drug therapyNausea/chemically inducedParkinson Disease/complicationsParkinson Disease/drug therapyPhenylcarbamates/adverse effectsPhenylcarbamates/therapeutic useRivastigmine
Substances: See more » Antiparkinson AgentsCholinesterase InhibitorsPhenylcarbamatesRivastigmine
Year: 2004 PMID: 15590960 DOI: 10.1056/NEJMe048305
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245